Phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00951496?term=GOG-0252&rank=1

2. Intervention

   Cisplatin

3. Intervention

   Paclitaxel

4. Intervention

   Carboplatin

5. Additional Topic(s)

   Intraperitoneal infusion

6. Additional Topic(s)

   Intravenous infusion

7. Additional Topic(s)

   Progression-free survival

8. Resource Description

   The purpose of this study is to determine if one or both of the proposed intraperitoneal chemotherapy regimens improves the progression-free survival (PFS) event rate compared to standard intravenous chemotherapy for first-line treatment of patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer. If both IP regimens significantly improve the PFS event rate compared to the standard regimen, then a second study objective is to determine whether IP cisplatin and IV paclitaxel on day one plus IP paclitaxel on day eight improves the PFS event rate when compared to the IP carboplatin and IV paclitaxel.

9. Contact

   Berenberg, Jeffrey

10. PI

    Berenberg, Jeffrey

11. Topic

    peritoneal carcinoma

12. Topic

    fallopian tube cancer

13. Topic

    ovarian cancer

14. Study Population

    Females aged 18 and older with histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.

15. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=650601&version=healthprofessional

16. Funded by

    Gynecologic Oncology Group

17. Phase

    Phase 3 clinical trial

18. Performed by

    Clinical Protocol & Data Management Shared Resource